ReviewJournal of leukocyte biology2019
Macrophage immunomodulation in chronic osteolytic diseases-the case of periodontitis.
Review in Journal of leukocyte biology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 60 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
60 citing papers in PubMed, 112 citations in OpenAlex.
- Single-Cell and Machine Learning Analysis Reveal Novel Inflammatory Macrophage Subtypes and Biomarkers in Periodontitis.International dental journal · 2026Article
- Local drug delivery systems for the periodontal microenvironment: from barrier penetration to multilevel synergy.Frontiers in pharmacology · 2026Review
- Functions of Macrophages in Periodontal Disease Progression and Gingival Tissue Homeostasis.Advances in experimental medicine and biology · 2026Review
- Comparative Proteomic Analysis of Dental-Origin Stem Cells: Insights into Regenerative Potential.Stem cell reviews and reports · 2025Article
- Customized Hydrogel System for the Spatiotemporal Sequential Treatment of Periodontitis Propelled by ZEB1.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Induced pluripotent stem cell-derived mesenchymal stem cells (iMSCs) inhibit M1 macrophage polarization and reduce alveolar bone loss associated with periodontitis.Stem cell research & therapy · 2025Article
- Fibroblast derived C3 promotes the progression of experimental periodontitis through macrophage M1 polarization and osteoclast differentiation.International journal of oral science · 2025Article
- Identification of Potential Biomarkers and Therapeutic Targets for Periodontitis.International dental journal · 2025Article
- Ginsenoside Rg1 regulating inflammatory response and bone-remodeling through Keap1/Nrf2 signaling pathway in rats with periodontitis.Scientific reports · 2025Article
- New Insights in Natural Bioactive Compounds for Periodontal Disease: Advanced Molecular Mechanisms and Therapeutic Potential.Molecules (Basel, Switzerland) · 2025Review
- Mesenchymal stem cell-derived extracellular vesicles in periodontal bone repair.Journal of molecular medicine (Berlin, Germany) · 2025Review
- Mechanisms and therapeutic perspectives of mitochondrial dysfunction of macrophages in periodontitis.Frontiers in cellular and infection microbiology · 2025Review
- Review
- Mesenchymal stem cell-derived exosomes: a potential cell-free therapy for orthodontic tooth stability management.Stem cell research & therapy · 2024Review
- Effect of chondroitin sulfate modified polyethyleneimine on mediating oligodeoxynucleotide YW002 in the treatment of periodontitis.RSC advances · 2024Article
- Assessment of the Effect on Periodontitis of Antibiotic Therapy and Bacterial Lysate Treatment.International journal of molecular sciences · 2024Article
- Bioactive materials from berberine-treated human bone marrow mesenchymal stem cells promote alveolar bone regeneration by regulating macrophage polarization.Science China. Life sciences · 2024Article
- Identifying Differences in Molecular Characteristics Relevant for Remodeling of Periodontal Ligament Stem Cells from the Upper and Lower Jaw.International journal of molecular sciences · 2024Article
- Association between the systemic immune inflammation index and periodontitis: a cross-sectional study.Journal of translational medicine · 2024Article
- Restoring periodontal tissue homoeostasis prevents cognitive decline by reducing the number of Serpina3nInnovation (Cambridge (Mass.)) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
Abstract
Periodontitis (PD) is a chronic osteolytic disease that shares pathogenic inflammatory features with other conditions associated with nonresolving inflammation. A hallmark of PD is inflammation-mediated alveolar bone loss. Myeloid cells, in particular polymorphonuclear neutrophils (PMN) and macrophages (Mac), are essential players in PD by control of gingival biofilm pathogenicity, activation of adaptive immunity, as well as nonresolving inflammation and collateral tissue damage. Despite mounting evidence of significant innate immune implications to PD progression and healing after therapy, myeloid cell markers and targets for immune modulation have not been validated for clinical use. The remarkable plasticity of monocytes/Mac in response to local activation factors enables these cells to play central roles in inflammation and restoration of tissue homeostasis and provides opportunities for biomarker and therapeutic target discovery for management of chronic inflammatory conditions, including osteolytic diseases such as PD and arthritis. Along a wide spectrum of activation states ranging from proinflammatory to pro-resolving, Macs respond to environmental changes in a site-specific manner in virtually all tissues. This review summarizes the existing evidence on Mac immunomodulation therapies for osteolytic diseases in the broader context of conditions associated with nonresolving inflammation, and discusses osteoimmune implications of Macs in PD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.